Designing switchable nanosystems for medical application

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 307-316

  Lehner, Roman ^a   Wang, Xueya ^a   Wolf, Marc ^a   Hunziker, Patrick ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Diagnosis; Medical application; Nanocarrier; Stimuli responsiveness; Therapy

Indexed keywords

CARRIER SYSTEMS; CLINICAL EXPERIENCE; CLINICAL TRIAL; CONTROLLED SYSTEM; ENZYMATIC ACTIVITIES; IMAGING AGENT; NANO SCALE; NANOCARRIERS; NANOMATERIAL; PRECLINICAL DEVELOPMENT; REDOX POTENTIALS; SCIENTIFIC FIELDS; SIDE EFFECT; SPATIOTEMPORAL CONTROL; STIMULI-RESPONSIVE; STIMULI-RESPONSIVENESS; SWITCHABLE; THERAPEUTIC EFFECTS; THERAPY;

DIAGNOSIS; DISEASE CONTROL; DRUG INTERACTIONS; INTELLIGENT AGENTS; MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; NUCLEIC ACIDS; PROTEINS; REDOX REACTIONS;

NANOSYSTEMS;

ANTIBODY; BORON; CASPASE 3; CYCLODEXTRIN; DOXORUBICIN; GELATINASE A; GLUTATHIONE; IRON OXIDE; LIPOSOME; MATRIX METALLOPROTEINASE; MAYTANSINE; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; NUCLEIC ACID; PACLITAXEL; PEPTIDE; SERUM ALBUMIN; SMALL INTERFERING RNA; TRASTUZUMAB; VERTEPORFIN;

BREAST CANCER; COLON CANCER; DRUG RELEASE; ELECTROMAGNETIC RADIATION; ENDOCYTOSIS; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IN VITRO STUDY; LEWIS CARCINOMA; LIVER CANCER; MICELLE; NANOENGINEERING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PARTICLE SIZE; PH; PRIORITY JOURNAL; RADIATION; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TEMPERATURE; TUMOR CELL; ULTRASOUND;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES;

EID: 84862661182     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.040     Document Type: Review

References (167)

1. Y. Li, H. Dong, K. Wang, D. Shi, X. Zhang, R. Zhuo, Stimulus-responsive polymeric nanoparticles for biomedical applications, Sci. China Chem. 53 (2010) 447-457.
2. V.P. Torchilin, Multifunctional nanocarriers, Adv. Drug Deliv. Rev. 58 (2006) 1532-1555.
3. S. Ganta, H. Devalapally, A. Shahiwala, M. Amiji, A review of stimuli-responsive nanocarriers for drug and gene delivery, J. Control. Release 126 (2008) 187-204.
4. E.S. Lee, Z. Gao, Y.H. Bae, Recent progress in tumor pH targeting nanotechnology, J. Control. Release 132 (2008) 164-170.
5. L.E. Gerweck, K. Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, Cancer Res. 56 (1996) 1194-1198.
6. O. Onaca, R. Enea, D.W. Hughes, W. Meier, Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery, Macromol. Biosci. 9 (2009) 129-139.
7. A. Makhlof, Y. Tozuka, H. Takeuchi, Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery, Eur. J. Pharm. Sci. 42 (2011) 445-451.
8. J.-W. Yoo, N. Giri, C.H. Lee, pH-sensitive Eudragit nanoparticles for mucosal drug delivery, Int. J. Pharm. 403 (2011) 262-267.
9. M.S. nchez, F.J. Aranda, J.A. Teruel, A. Ortiz, New pH-sensitive liposomes containing phosphatidylethanolamine and a bacterial dirhamnolipid, Chem. Phys. Lipids 164 (2011) 16-23.
10. E.E. Geisert, N.A. Del Mar, J.L. Owens, E.G. Holmberg, Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes, Neurosci. Lett. 184 (1995) 40-43.
11. V. Torchilin, Multifunctional and stimuli-sensitive pharmaceutical nanocarriers, Eur. J. Pharm. Biopharm. 71 (2009) 431-444.
12. D. Kim, E.S. Lee, K.T. Oh, Z.G. Gao, Y.H. Bae, Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH, Small 4 (2008) 2043-2050.
13. P. Broz, S. Driamov, J. Ziegler, N. Ben-Haim, S. Marsch, W. Meier, P. Hunziker, Toward intelligent nanosize bioreactors: a pH-switchable, channel-equipped, functional polymer nanocontainer, Nano Lett. 6 (2006) 2349-2353.
14. A. Ranquin, W. Versées, W. Meier, J. Steyaert, P. Van Gelder, Therapeutic nanoreactors: combining chemistry and biology in a novel triblock copolymer drug delivery system, Nano Lett. 5 (2005) 2220-2224.
15. R. Koebnik, K.P. Locher, P. Van Gelder, Structure and function of bacterial outer membrane proteins: barrels in a nutshell, Mol. Microbiol. 37 (2000) 239-253.
16. P. Broz, N. Ben-Haim, F. Santini, S. Marsch, K. Scheffler, W. Meier, P. Hunziker, Polymer vesicles loaded with precipitated gadolinium nanoparticles: a novel target-specific contrast agent for magnetic resonance imaging, Eur. J. Nanomed. 2 (2009) 1-6.
17. H. Mok, O. Veiseh, C. Fang, F.M. Kievit, F.Y. Wang, J.O. Park, M. Zhang, pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells, Mol. Pharm. 7 (2010) 1930-1939.
18. V.A. Sethuraman, Y.H. Bae, TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors, J. Control. Release 118 (2007) 216-224.
19. A.A. Kale, V.P. Torchilin, Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes, J. Drug Target. 15 (2007) 538-545.
20. H. Koo, G.-W. Jin, H. Kang, Y. Lee, K. Nam, C.Z. Bai, J.-S. Park, Biodegradable branched poly(ethylenimine sulfide) for gene delivery, Biomaterials 31 (2010) 988-997.
21. P.D.W. Eckford, F.J. Sharom, ABC efflux pump-based resistance to chemotherapy drugs, Chem. Rev. 109 (2009) 2989-3011.
22. R. Liu, X. Zhao, T. Wu, P. Feng, Tunable redox-responsive hybrid nanogated ensembles, J. Am. Chem. Soc. 130 (2008) 14418-14419.
23. H. Kim, S. Kim, C. Park, H. Lee, H.J. Park, C. Kim, Glutathione-induced intracellular release of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers, Adv. Mater. Weinheim 22 (2010) 4280-4283.
24. Z. Luo, K. Cai, Y. Hu, L. Zhao, P. Liu, L. Duan, W. Yang, Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery, Angew. Chem. Int. Ed. 50 (2010) 640-643.
25. Z. Huang, W. Li, J. MacKay, F. Szoka, Thiocholesterol-based lipids for ordered assembly of bioresponsive gene carriers, Mol. Ther. 11 (2005) 409-417.
26. D. Kirpotin, K. Hong, N. Mullah, D. Papahadjopoulos, S. Zalipsky, Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol), FEBS Lett. 388 (1996) 115-118.
27. A. Gabizon, D. Tzemach, A. Horowitz, H. Shmeeda, J. Yeh, S. Zalipsky, Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes, Clin. Cancer Res. (2006) 1913-1920.
28. K.R. West, S. Otto, Reversible covalent chemistry in drug delivery, Curr. Drug Discov. Technol. 2 (2005) 123-160.
29. I. Niculescu-Duvaz, Technology evaluation: gemtuzumab ozogamicin, Celltech Group, Curr. Opin. Mol. Ther. 2 (2000) 691-696.
30. D. Sbardella, G.F. Fasciglione, M. Gioia, C. Ciaccio, G.R. Tundo, S. Marini, M. Coletta, Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes, Mol. Aspects Med. 33 (2012) 119-208.
31. P. Vihinen, R. Ala-aho, V. Kahari, Matrix metalloproteinases as therapeutic targets in cancer, Curr. Cancer Drug Targets 5 (2005) 203-220.
32. T. Turpeenniemi-Hujanen, Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers, Biochimie 87 (2005) 287-297.
33. V.K. Garripelli, J.-K. Kim, S. Son, W.J. Kim, M.A. Repka, S. Jo, Matrix metalloproteinase-sensitive thermogelling polymer for bioresponsive local drug delivery, Acta Biomater. 7 (2011) 1984-1992.
34. A.I. Elegbede, J. Banerjee, A.J. Hanson, S. Tobwala, B. Ganguli, R. Wang, X. Lu, D.K. Srivastava, S. Mallik, Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9, J. Am. Chem. Soc. 130 (2008) 10633-10642.
35. T. Jiang, E.S. Olson, Q.T. Nguyen, M. Roy, P.A. Jennings, R.Y. Tsien, Tumor imaging by means of proteolytic activation of cell-penetrating peptides, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17867-17872.
36. E.S. Olson, T.A. Aguilera, T. Jiang, L.G. Ellies, Q.T. Nguyen, E.H. Wong, L.A. Gross, R.Y. Tsien, In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer, Integr. Biol. 1 (2009) 382.
37. C. Park, H. Kim, S. Kim, C. Kim, Enzyme responsive nanocontainers with cyclodextrin gatekeepers and synergistic effects in release of guests, J. Am. Chem. Soc. 131 (2009) 16614-16615.
38. A. Bernardos, E. Aznar, M.D. Marcos, R. Martinez-Mañez, F. Sancenon, J. Soto, J.M. Barat, P. Amoros, Enzyme-responsive controlled release using mesoporous silica supports capped with lactose, Angew. Chem. Int. Ed. Engl. 48 (2009) 5884-5887.
39. A. Bernardos, L. Mondragon, E. Aznar, M.D. Marcos, R. Martinez-Mañez, F. Sancenon, J. Soto, J.M. Barat, E.P. Paya, C. Guillem, Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides", ACS Nano 4 (2010) 6353-6368.
40. K. Patel, S. Angelos, W.R. Dichtel, A. Coskun, Y.-W. Yang, J.I. Zink, J.F. Stoddart, Enzyme-responsive snap-top covered silica nanocontainers, J. Am. Chem. Soc. 130 (2008) 2382-2383.
41. P.D. Thornton, R.J. Mart, S.J. Webb, R.V. Ulijn, Enzyme-responsive hydrogel particles for the controlled release of proteins: designing peptide actuators to match payload, Soft Matter 4 (2008) 821.
42. N. Ben-Haim, P. Broz, S. Marsch, W. Meier, P. Hunziker, Cell-specific integration of artificial organelles based on functionalized polymer vesicles, Nano Lett. 8 (2008) 1368-1373.
43. F. Meng, Z. Zhong, J. Feijen, Stimuli-responsive polymersomes for programmed drug delivery, Biomacromolecules 10 (2009) 197-209.
44. C. Kojima, Design of stimuli-responsive dendrimers, Expert Opin. Drug Deliv. 7 (2010) 307-319.
45. K. Kono, S. Nakashima, D. Kokuryo, I. Aoki, H. Shimomoto, S. Aoshima, K. Maruyama, E. Yuba, C. Kojima, A. Harada, Y. Ishizaka, Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy, Biomaterials 32 (2011) 1387-1395.
46. H. Wei, X. Zhang, C. Cheng, S.-X. Cheng, R.-X. Zhuo, Self-assembled, thermosensitive micelles of a star block copolymer based on PMMA and PNIPAAm for controlled drug delivery, Biomaterials 28 (2007) 99-107.
47. S.H. Lee, S.H. Choi, S.H. Kim, T.G. Park, Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: swelling induced physical disruption of endosome by cold shock, J. Control. Release 125 (2008) 25-32.
48. S.H. Choi, S.H. Lee, T.G. Park, Temperature-sensitive pluronic/poly (ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment, Biomacromolecules 7 (2006) 1864-1870.
49. L.H. Lindner, M.E. Eichhorn, H. Eibl, N. Teichert, M. Schmitt-Sody, R.D. Issels, M. Dellian, Novel temperature-sensitive liposomes with prolonged circulation time, Clin. Cancer Res. 10 (2004) 2168-2178.
50. M.H. Gaber, K. Hong, S.K. Huang, D. Papahadjopoulos, Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serumand human plasma, Pharm. Res. 12 (1995) 1407-1416.
51. D. Needham, G. Anyarambhatla, G. Kong, M.W. Dewhirst, A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res. 60 (2000) 1197-1201.
52. G. Kong, G. Anyarambhatla, W.P. Petros, R.D. Braun, O.M. Colvin, D. Needham, M.W. Dewhirst, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release, Cancer Res. 60 (2000) 6950-6957.
53. T. Tagami, M.J. Ernsting, S.-D. Li, Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin, J. Control. Release 152 (2011) 303-309.
54. J.S. Katz, J.A. Burdick, Light-responsive biomaterials: development and applications, Macromol. Biosci. 10 (2010) 339-348.
55. N. Nishiyama, A. Iriyama, W.-D. Jang, K. Miyata, K. Itaka, Y. Inoue, H. Takahashi, Y. Yanagi, Y. Tamaki, H. Koyama, K. Kataoka, Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer, Nat. Mater. 4 (2005) 934-941.
56. J. Babin, M. Pelletier, M. Lepage, J.-F. Allard, D. Morris, Y. Zhao, A new two-photon-sensitive block copolymer nanocarrier, Angew. Chem. Int. Ed. Engl. 48 (2009) 3329-3332.
57. L. Sun, Y. Yang, C.-M. Dong, Y. Wei, Two-photon-sensitive and sugar-targeted nanocarriers from degradable and dendritic amphiphiles, Small 7 (2011) 401-406.
58. T. Koyama, K. Hatano, K. Matsuoka, Y. Esumi, D. Terunuma, Synthesis and characterization of photo-responsive carbosilane dendrimers, Molecules 14 (2009) 2226-2234.
59. N. Fomina, C. McFearin, M. Sermsakdi, O. Edigin, A. Almutairi, UV and near-IR triggered release from polymeric nanoparticles, J. Am. Chem. Soc. 132 (2010) 9540-9542.
60. E. Cabane, V. Malinova, W. Meier, Synthesis of photocleavable amphiphilic block copolymers: toward the design of photosensitive nanocarriers, Macromol. Chem. Phys. 211 (2010) 1847-1856.
61. S. Pervaiz, M. Olivo, Art and science of photodynamic therapy, Clin. Exp. Pharmacol. Physiol. 33 (2006) 551-556.
62. J.G. Christie, U.B. Kompella, Ophthalmic light sensitive nanocarrier systems, Drug Discov. Today 13 (2008) 124-134.
63. A. Juarranz, P. Jaén, F. Sanz-Rodríguez, J. Cuevas, S. González, Photodynamic therapy of cancer. Basic principles and applications, Clin. Transl. Oncol. 10 (2008) 148-154.
64. A.G. Skirtach, A.A. Antipov, D.G. Shchukin, G.B. Sukhorukov, Remote activation of capsules containing Ag nanoparticles and IR dye by laser light, Langmuir 20 (2004) 6988-6992.
65. T. Furuta, S.S. Wang, J.L. Dantzker, T.M. Dore, W.J. Bybee, E.M. Callaway, W. Denk, R.Y. Tsien, Brominated 7-hydroxycoumarin-4-ylmethyls: photolabile protecting groups with biologically useful cross-sections for two photon photolysis, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1193-1200.
66. S. Carregal-Romero, M. Ochs, P. Rivera-Gil, C. Ganas, A.M. Pavlov, G.B. Sukhorukov, W.J. Parak, NIR-light triggered delivery of macromolecules into the cytosol, J. Control. Release (2012) 1-8.
67. G.C.R. Ellis-Davies, Caged compounds: photorelease technology for control of cellular chemistry and physiology, Nat. Methods 4 (2007) 619-628.
68. V. Mikat, A. Heckel, Light-dependent RNA interference with nucleobase-caged siRNAs, RNA 13 (2007) 2341-2347.
69. J.H. Kaplan, B. Forbush, J.F. Hoffman, Rapid photolytic release of adenosine 5′-triphosphate from a protected analogue: utilization by the Na:K pump of human red blood cell ghosts, Biochemistry 17 (1978) 1929-1935.
70. D.D. Young, M.O. Lively, A. Deiters, Activation and deactivation of DNAzyme and antisense function with light for the photochemical regulation of gene expression in mammalian cells, J. Am. Chem. Soc. 132 (2010) 6183-6193.
71. S. Yamaguchi, Y. Chen, S. Nakajima, T. Furuta, T. Nagamune, Light-activated gene expression from site-specific caged DNA with a biotinylated photolabile protection group, Chem. Commun. 46 (2010) 2244-2246.
72. H. Ando, T. Furuta, R.Y. Tsien, H. Okamoto, Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos, Nat. Genet. 28 (2001) 317-325.
73. W.T. Monroe, M.M. McQuain, M.S. Chang, J.S. Alexander, F.R. Haselton, Targeting expression with light using caged DNA, J. Biol. Chem. 274 (1999) 20895-20900.
74. S. Shah, S. Rangarajan, S.H. Friedman, Light-activated RNA interference, Angew. Chem. Int. Ed. Engl. 44 (2005) 1328-1332.
75. G.A. Husseini, W.G. Pitt, Ultrasonic-activated micellar drug delivery for cancer treatment, J. Pharm. Sci. 98 (2009) 795-811.
76. N. Rapoport, Z. Gao, A. Kennedy, Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy, JNCI J. Natl. Cancer Inst. 99 (2007) 1095-1106.
77. Y. Inoue, K. Goto, T. Hayashi, M. Hayashi, Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer, Int. J. Urol. 18 (2011) 358-363.
78. S.E. Jung, S.H. Cho, J.H. Jang, J.-Y. Han, High-intensity focused ultrasound ablation in hepatic and pancreatic cancer: complications, Abdom. Imaging 36 (2011) 185-195.
79. M.R. Böhmer, A.L. Klibanov, K. Tiemann, C.S. Hall, H. Gruell, O.C. Steinbach, Ultrasound triggered image-guided drug delivery, Eur. J. Radiol. 70 (2009) 242-253.
80. N.Y. Rapoport, D.A. Christensen, H.D. Fain, L. Barrows, Z. Gao, Ultrasound-triggered drug targeting of tumors in vitro and in vivo, Ultrasonics 42 (2004) 943-950.
81. G.A. Husseini, M.A. Diaz de la Rosa, T. Gabuji, Y. Zeng, D.A. Christensen, W.G. Pitt, Release of doxorubicin from unstabilized and stabilized micelles under the action of ultrasound, J. Nanosci. Nanotechnol. 7 (2007) 1028-1033.
82. P.M. Shah, R. Gramiak, D.H. Kramer, P.N. Yu, Determinants of atrial (S4) and ventricular (S3) gallop sounds in primary myocardial disease, N. Engl. J. Med. 278 (1968) 753-758.
83. F. Kiessling, S. Fokong, P. Koczera, W. Lederle, T. Lammers, Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics, J. Nucl. Med. 53 (2012) 345-348.
84. R. Suzuki, Y. Oda, N. Utoguchi, K. Maruyama, Development of ultrasonic cancer therapy using ultrasound sensitive liposome, Yakugaku Zasshi 130 (2010) 1665-1670.
85. F. Yan, X. Li, Q. Jin, C. Jiang, Z. Zhang, T. Ling, B. Qiu, H. Zheng, Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-assisted chemotherapy in breast cancer cells, Ultrasound Med. Biol. 37 (2011) 768-779.
86. M.S. Tartis, J. McCallan, A.F.H. Lum, R. LaBell, S.M. Stieger, T.O. Matsunaga, K.W. Ferrara, Therapeutic effects of paclitaxel-containing ultrasound contrast agents, Ultrasound Med. Biol. 32 (2006) 1771-1780.
87. R. Suzuki, Y. Oda, N. Utoguchi, K. Maruyama, Progress in the development of ultrasound-mediated gene delivery systems utilizing nano- and microbubbles, J. Control. Release 149 (2011) 36-41.
88. M. Takahashi, K. Kido, A. Aoi, H. Furukawa, M. Ono, T. Kodama, Spinal gene transfer using ultrasound and microbubbles, J. Control. Release 117 (2007) 267-272.
89. M.C. Deshpande, M.R. Prausnitz, Synergistic effect of ultrasound and PEI on DNA transfection in vitro, J. Control. Release 118 (2007) 126-135.
90. Y. Negishi, Y. Endo, T. Fukuyama, R. Suzuki, T. Takizawa, D. Omata, K. Maruyama, Y. Aramaki, Delivery of siRNA into the cytoplasm by liposomal bubbles and ultrasound, J. Control. Release 132 (2008) 124-130.
91. K. Otani, K. Yamahara, S. Ohnishi, H. Obata, S. Kitamura, N. Nagaya, Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles, J. Control. Release 133 (2009) 146-153.
92. H. Yanagie, Y. Fujii, T. Takahashi, T. Tomita, Y. Fukano, K. Hasumi, H. Nariuchi, T. Yasuda, M. Sekiguchi, H. Uchida, Boron neutron capture therapy using 10B entrapped anti-CEA immunoliposome, Hum. Cell 2 (1989) 290-296.
93. S. Tsunoda, O. Mazda, Y. Oda, Y. Iida, S. Akabame, T. Kishida, M. Shin-Ya, H. Asada, S. Gojo, J. Imanishi, H. Matsubara, Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart, Biochem. Biophys. Res. Commun. 336 (2005) 118-127.
94. A. Halbreich, J. Roger, J.N. Pons, D. Geldwerth, M.F. Da Silva, M. Roudier, J.C. Bacri, Biomedical applications of maghemite ferrofluid, Biochimie 80 (1998) 379-390.
95. Q.A. Pankhurst, J. Connolly, S. Jones, J. Dobson, Applications of magnetic nanoparticles in biomedicine, J. Phys. D: Appl. Phys. 36 (2003) R167.
96. M. Suzuki, M. Shinkai, H. Honda, T. Kobayashi, Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes, Melanoma Res. 13 (2003) 129-135.
97. R. Weissleder, D.D. Stark, C.C. Compton, J. Wittenberg, J.T. Ferrucci, Ferrite-enhanced MR imaging of hepatic lymphoma: an experimental study in rats, AJR Am. J. Roentgenol. 149 (1987) 1161-1165.
98. R. Weissleder, G. Elizondo, J. Wittenberg, A.S. Lee, L. Josephson, T.J. Brady, Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging, Radiology 175 (1990) 494-498.
99. R. Weissleder, D.D. Stark, G. Elizondo, P.F. Hahn, C. Compton, S. Saini, J. Wittenber, J.T. Ferrucci, MRI of hepatic lymphoma, Magn. Reson. Imaging 6 (1988) 675-681.
100. J. Grimm, J.M. Perez, L. Josephson, R. Weissleder, Novel nanosensors for rapid analysis of telomerase activity, Cancer Res. 64 (2004) 639-643.
101. J.M. Perez, L. Josephson, T. O'Loughlin, D. Högemann, R. Weissleder, Magnetic relaxation switches capable of sensing molecular interactions, Nat. Biotechnol. 20 (2002) 816-820.
102. M. Hans, A. Lowman, Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci. 6 (2002) 319-327.
103. M. Arsianti, M. Lim, C.P. Marquis, R. Amal, Polyethylenimine based magnetic iron-oxide vector: the effect of vector component assembly on cellular entry mechanism, intracellular localization, and cellular viability, Biomacromolecules 11 (2010) 2521-2531.
104. F.N. Al-Deen, J. Ho, C. Selomulya, C. Ma, R. Coppel, Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine, Langmuir 27 (2011) 3703-3712.
105. P. Pouponneau, J.-C. Leroux, G. Soulez, L. Gaboury, S. Martel, Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation, Biomaterials 32 (2011) 3481-3486.
106. P. Pouponneau, J.-C. Leroux, S. Martel, Magnetic nanoparticles encapsulated into biodegradable microparticles steered with an upgraded magnetic resonance imaging system for tumor chemoembolization, Biomaterials 30 (2009) 6327-6332.
107. P. Pouponneau, O. Savadogo, T. Napporn, L. Yahia, S. Martel, Corrosion study of iron-cobalt alloys for MRI-based propulsion embedded in untethered microdevices operating in the vascular network, J. Biomed. Mater. Res. B Appl. Biomater. 93 (2010) 203-211.
108. A.A.M. Elsherbini, M. Saber, M. Aggag, A. El-Shahawy, H.A.A. Shokier, Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging, Magn. Reson. Imaging 29 (2011) 272-280.
109. C.S.S.R. Kumar, F. Mohammad, Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery, Adv. Drug Deliv. Rev. 63 (2011) (2011) 789-808.
110. G. Liang, S. Cai, P. Zhang, Y. Peng, H. Chen, S. Zhang, J. Kong, Magnetic relaxation switch and colorimetric detection of thrombin using aptamer-functionalized gold-coated iron oxide nanoparticles, Anal. Chim. Acta 689 (2011) 243-249.
111. M. Lewin, N. Carlesso, C.H. Tung, X.W. Tang, D. Cory, D.T. Scadden, R. Weissleder, Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells, Nat. Biotechnol. 18 (2000) 410-414.
112. R. Weissleder, A. Moore, U. Mahmood, R. Bhorade, H. Benveniste, E.A. Chiocca, J.W. Tjarks, In vivo magnetic resonance imaging of transgene expression, Nat. Med. 6 (2000) 351-355.
113. J.M. Perez, L. Josephson, R. Weissleder, Use of magnetic nanoparticles as nanosensors to probe for molecular interactions, ChemBioChem 5 (2004) 261-264.
114. C. Alexiou, W. Arnold, R.J. Klein, F.G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. Wagenpfeil, A.S. Lübbe, Locoregional cancer treatment with magnetic drug targeting, Cancer Res. 60 (2000) 6641-6648.
115. G. Locher, Biological effects and therapeutic possibilities of neutrons, Am. J. Roentgenol. Radium 36 (1936) 1-13.
116. C. Salt, A. Lennox, M. Takagaki, J. Maguire, N. Hosmane, Boron and gadolinium neutron capture therapy, Russ. Chem. Bull. (2004) 1871-1888.
117. S.J. Walker, Boron neutron capture therapy: principles and prospects, Radiography 4 (1998) 211-219.
118. K.C. Hwang, P.D. Lai, C.-S. Chiang, P.-J. Wang, C.-J. Yuan, Neutron capture nucleicontaining carbon nanoparticles for destruction of cancer cells, Biomaterials 31 (2010) 8419-8425.
119. M.F. Hawthorne, New horizons for therapy based on the boron neutron capture reaction, Mol. Med. Today 4 (1998) 174-181.
120. R.F. Barth, J.A. Coderre, M.G.H. Vicente, T.E. Blue, Boron neutron capture therapy of cancer: current status and future prospects, Clin. Cancer Res. 11 (2005) 3987-4002.
121. R.F. Martin, G. D'Cunha, M. Pardee, B.J. Allen, Induction of DNA double-strand breaks by 157Gd neutron capture, Pigment Cell Res. 2 (1989) 330-332.
122. A. Wittig, F. Stecher-Rasmussen, R.A. Hilger, J. Rassow, P. Mauri, W. Sauerwein, Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention, Appl. Radiat. Isot. 69 (2011) 1760-1764.
123. K. Sköld, B. H-Stenstam, A.Z. Diaz, V. Giusti, L. Pellettieri, J.W. Hopewell, Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f, Acta Neurol. Scand. 122 (2010) 58-62.
124. H. Ichikawa, E. Taniguchi, T. Fujimoto, Y. Fukumori, Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutroncapture therapy of cancer, Appl. Radiat. Isot. 67 (2009) S111-S114.
125. H. Yanagie, T. Tomita, H. Kobayashi, Y. Fujii, T. Takahashi, K. Hasumi, H. Nariuchi, M. Sekiguchi, Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model, Br. J. Cancer 63 (1991) 522-526.
126. S.M. Stephenson, W. Yang, P.J. Stevens, W. Tjarks, R.F. Barth, R.J. Lee, Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy, Anticancer. Res. 23 (2003) 3341-3345.
127. X.Q. Pan, H. Wang, R.J. Lee, Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes, Anticancer. Res. 22 (2002) 1629-1633.
128. E.B. Kullberg, Q. Wei, J. Capala, V. Giusti, P.-U. Malmström, L. Gedda, EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation, Int. J. Radiat. Biol. 81 (2005) 621-629.
129. E. Bohl Kullberg, N. Bergstrand, J. Carlsson, K. Edwards, M. Johnsson, S. Sjöberg, L. Gedda, Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents, Bioconjug. Chem. 13 (2002) 737-743.
130. Y. Miyajima, H. Nakamura, Y. Kuwata, J.-D. Lee, S. Masunaga, K. Ono, K. Maruyama, Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy, Bioconjug. Chem. 17 (2006) 1314-1320.
131. M. Shirakawa, T. Yamamto, K. Nakai, K. Aburai, S. Kawatobi, T. Tsurubuchi, Y. Yamamoto, Y. Yokoyama, H. Okuno, A. Matsumara, Synthesis and evaluation of a novel liposome containing BPA-peptide conjugate for BNCT, Appl. Radiat. Isot. 67 (2009) S88-S90.
132. M. Ueno, H.S. Ban, K. Nakai, R. Inomata, Y. Kaneda, A. Matsumura, H. Nakamura, Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy, Bioorg. Med. Chem. 18 (2010) 3059-3065.
133. M.F. Hawthorne, K. Shelly, Liposomes as drug delivery vehicles for boron agents, J. Neurooncol. 33 (1997) 53-58.
134. M.V. Backer, T.I. Gaynutdinov, V. Patel, A.K. Bandyopadhyaya, B.T.S. Thirumamagal, W. Tjarks, R.F. Barth, K. Claffey, J.M. Backer, Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature, Mol. Cancer Ther. 4 (2005) 1423-1429.
135. S. Shukla, G. Wu, M. Chatterjee, W. Yang, M. Sekido, L.A. Diop, R. Müller, J.J. Sudimack, R.J. Lee, R.F. Barth, W. Tjarks, Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy, Bioconjug. Chem. 14 (2003) 158-167.
136. T. Watanabe, H. Ichikawa, Y. Fukumori, Tumor accumulation of gadolinium in lipid-nanoparticles intravenously injected for neutron-capture therapy of cancer, Eur. J. Pharm. Biopharm. 54 (2002) 119-124.
137. M.O. Oyewumi, R.A. Yokel, M. Jay, T. Coakley, R.J. Mumper, Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice, J. Control. Release 95 (2004) 613-626.
138. U.M. Le, D.S. Shaker, B.R. Sloat, Z. Cui, A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors, Drug Dev. Ind. Pharm. 34 (2008) 413-418.
139. X. Li, X. Tian, J. Zhang, X. Zhao, X. Chen, Y. Jiang, D. Wang, W. Pan, In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel, Int. J. Nanomedicine 6 (2011) 1167-1184.
140. Y. Yamada, Y. Shinohara, T. Kakudo, S. Chaki, S. Futaki, H. Kamiya, H. Harashima, Mitochondrial delivery of mastoparan with transferrin liposornes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy, Int. J. Pharm. 303 (2005) 1-7.
141. W.S. Shim, J.-H. Kim, K. Kim, Y.-S. Kim, R.-W. Park, I.-S. Kim, I.C. Kwon, D.S. Lee, pH- and temperature-sensitive, injectable, biodegradable block copolymer hydrogels as carriers for paclitaxel, Int. J. Pharm. 331 (2007) 11-18.
142. M.-H. Dufresne, D.L. Garrec, V. Sant, J.-C. Leroux, M. Ranger, Preparation and characterization of water-soluble pH-sensitive nanocarriers for drug delivery, Int. J. Pharm. 277 (2004) 81-90.
143. R.J. Lutz, K.R. Whiteman, Antibody-maytansinoid conjugates for the treatment of myeloma, MAbs 1 (2009) 548-551.
144. H.A. Burris, H.S. Rugo, S.J. Vukelja, C.L. Vogel, R.A. Borson, S. Limentani, E. Tan-Chiu, I.E. Krop, R.A. Michaelson, S. Girish, et al., Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy, J. Clin. Oncol. 29 (2011) 398-405.
145. M. Zhao, A. Biswas, B. Hu, K.-I. Joo, P. Wang, Z. Gu, Y. Tang, Redox-responsive nanocapsules for intracellular protein delivery, Biomaterials 32 (2011) 5223-5230.
146. S. Cerritelli, D. Velluto, J.A. Hubbell, PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery, Biomacromolecules 8 (2007) 1966-1972.
147. N. Song, W. Liu, Q. Tu, R. Liu, Y. Zhang, J. Wang, Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery, Colloids Surf. B Biointerfaces 87 (2011) 454-463.
148. R.S. Navath, Y.E. Kurtoglu, B. Wang, S. Kannan, R. Romero, R.M. Kannan, Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels, Bioconjug. Chem. 19 (2008) 2446-2455.
149. H. Hatakeyama, H. Akita, E. Ishida, K. Hashimoto, H. Kobayashi, T. Aoki, J. Yasuda, K. Obata, H. Kikuchi, T. Ishida, H. Kiwada, H. Harashima, Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes, Int. J. Pharm. 342 (2007) 194-200.
150. S.-H. Lim, Y.-I. Jeong, K.-S. Moon, H.-H. Ryu, Y.-H. Jin, S.-G. Jin, T.-Y. Jung, I.-Y. Kim, S.-S. Kang, S. Jung, Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells, Int. J. Pharm. 387 (2010) 209-214.
151. G.Y. Lee, K. Park, S.Y. Kim, Y. Byun, MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin, Eur. J. Pharm. Biopharm. 67 (2007) 646-654.
152. H.D. Han, M.S. Choi, T. Hwang, C.K. Song, H. Seong, T.W. Kim, H.S. Choi, B.C. Shin, Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes, J. Pharm. Sci. 95 (2006) 1909-1917.
153. S. Dromi, V. Frenkel, A. Luk, B. Traughber, M. Angstadt, M. Bur, J. Poff, J. Xie, S.K. Libutti, K.C.P. Li, B.J. Wood, Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect, Clin. Cancer Res. 13 (2007) 2722-2727.
154. A. Igarashi, H. Konno, T. Tanaka, S. Nakamura, Y. Sadzuka, T. Hirano, Y. Fujise, Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer, Toxicol. Lett. 145 (2003) 133-141.
155. A. Marina, H. Suna, G.A. Husseinib, W.G. Pittb, D.A. Christensena, N.Y. Rapoporta, Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake, J. Control. Release 84 (2002) 39-47 (2002) 1-9.
156. R. Suzuki, T. Takizawa, Y. Negishi, N. Utoguchi, K. Sawamura, K. Tanaka, E. Namai, Y. Oda, Y. Matsumara, K. Maruyama, Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles, J. Control. Release 125 (2008) 137-144.
157. R. Suzuki, E. Namai, Y. Oda, N. Nishiie, S. Otake, R. Koshima, K. Hirata, Y. Taira, N. Utoguchi, Y. Negishi, S. Nakagawa, K. Maruyama, Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure, J. Control. Release 142 (2010) 245-250.
158. K. Maier-Hauff, F. Ulrich, D. Nestler, H. Niehoff, P. Wust, B. Thiesen, H. Orawa, V. Budach, A. Jordan, Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme, J. Neurooncol. 103 (2010) 317-324.
159. M.W. Wilson, R.K. Kerlan, N.A. Fidelman, A.P. Venook, J.M. LaBerge, J. Koda, R.L. Gordon, Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients, Radiology 230 (2004) 287-293.
160. M.K. Yu, Y.Y. Jeong, J. Park, S. Park, J.W. Kim, J.J. Min, K. Kim, S. Jon, Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo, Angew. Chem. Int. Ed. 47 (2008) 5362-5365.
161. J.W. Hopewell, T. Gorlia, L. Pellettieri, V. Giusti, B. H-Stenstam, K. Sköld, Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential, Appl. Radiat. Isot. 69 (2011) 1737-1740.
162. A.-K. Azab, M. Srebnik, V. Doviner, A. Rubinstein, Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers, J. Control. Release 106 (2005) 14-25.
163. P. Hunziker, Nanomedicine-shaping the medicine of the future, Z. Med. Phys. 22 (2012) 1-3.
164. A.A. Gabizon, Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy, Cancer Invest. 19 (2001) 424-436.
165. H. Hatakeyama, H. Akita, K. Kogure, H. Harashima, Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid, Yakugaku Zasshi 127 (2007) 1549-1556.
166. G. Saito, J.A. Swanson, K.-D. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv. Drug Deliv. Rev. 55 (2003) 199-215.
167. P. Hunziker, "Knowledge-based (personalized) medicine" instead of 'evidencebased (cohort) medicine'-applying nanoscience and computational science to create an effective, safe, curative and affordable medicine of the future, Eur. J. Nanomed. 2012 (2012) 1-2.